Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a major medical journal shows that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"People using these medications should be cognizant of the risk of rapid rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to starting weight in about 18 months.
Analyzing Approaches
The study, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with other pills.
Researchers note that individuals who shed pounds through lifestyle changes alone typically experience a slower creep back—around 100 grams monthly—after stopping.
Understanding the Rapid Regain
Experts suggest the way of the drugs accounts for the heightened regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than normal may cause the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means hunger is uncontrolled, making overeating far more likely."
A Lifelong Condition?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, due to the significant potential of weight regain, the therapy might need to be life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "emphasize the chronic nature of excess weight," similar to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have come off the jabs report a powerful resurgence of cravings.
"I experienced a trigger flipping and I was suddenly ravenous," recalled a patient.
This challenge is worsened if users have not developed sustainable dietary or behavioural changes during treatment.
Growing Interest
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while the jabs are potent agents for weight loss, they are not a magic solution and maintained weight loss likely depends on combined behavioural support.